Financials
Financial year 2025
Worth noting
- Little cash and receivables against the short-term debts.
Revenue
€ 17.7 million
▼ 4% vs 2024
Profit
Healthy€ 296,342
▼ 69% vs 2024
Debts
Normal€ 6.6 million
▼ 7% vs 2024
BELGIAN DIAGNOSTIC COMPANY from Marche-en-Famenne, company number BE0432680178, closed financial year 2025 with a result of € 296,342 after tax. For that financial year BELGIAN DIAGNOSTIC COMPANY recorded revenue of € 17.7 million and equity of € 1.9 million. Compared with financial year 2024, the result moved from € 951,854 to € 296,342. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
What happened at BELGIAN DIAGNOSTIC COMPANY?
What happened at BELGIAN DIAGNOSTIC COMPANY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jessica Wève stepped down as director. NBB
- NATALIS DEVELOPPEMENT SAS 991259714 stepped down as director. NBB
- MB SOLUTIONS srl SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 296,342 (▼ 69% vs 2024). Source: NBB ↗
- Jessica Wève became a director. NBB
- NATALIS DEVELOPPEMENT SAS 991259714 became a director. NBB
- MB SOLUTIONS srl SRL became a director. NBB
- New establishment in Marche-en-Famenne. KBO
In short
From € 778,526 loss in 2021 to € 296,342 profit in 2025.
Paid € 22,822 in corporate taxes since 2021.
Best year ever: 2024, with € 951,854 profit.
Pays suppliers within 51 days on average.
A new publication or filing at BELGIAN DIAGNOSTIC COMPANY? We notify you, reason included.
Follow BELGIAN DIAGNOSTIC COMPANYNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by INTERNATIONAL MEDICAL PRODUCTS (54%) and MEDIPREMA GROUP (46%). It owns 50% of BELDICO FRANCE SAS itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
NATALIS DEVELOPPEMENT SAS 991259714
Managing director · represented by Vincent Camus
since 2025 · until 2031
Director · represented by Marc Bemelmans
Also active at: INTERNATIONAL MEDICAL PRODUCTS
since 2025 · until 2031
Shareholders
MEDIPREMA GROUP
46%
Participations
BELDICO FRANCE SAS
50%
Establishments
Establishment units
Physical locations of this company
Aye, Rue André Feher 3
6900 Marche-en-Famenne
Aye, Rue André Feher 1
6900 Marche-en-Famenne
Active since 23 December 1987
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Details
- Company number
- 0432.680.178
- VAT number
- BE 0432.680.178
- Registered office
- Aye, Rue André Feher 3, 6900 Marche-en-Famenne
- Names & denominations
- BELGIAN DIAGNOSTIC COMPANY · BELDICO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 November 1987
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde
Vervaardiging van farmaceutische grondstoffen